Novartis Pharmaceuticals

Switzerland

1 Trial

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that has advanced MIJ821 — a selective GluN2B/NR2B NMDA receptor antagonist — through a Phase 2 proof-of-concept trial for treatment-resistant depression, exploring the same ketamine-like NMDA antagonism pathway. MIJ821's rapid-acting antidepressant mechanism is part of Novartis's broader CNS drug discovery pipeline.